OncoMatch/Clinical Trials/NCT03913117
Study of Treatment for HPV16+ ASC-US or LSIL
Is NCT03913117 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including pNGVL4aCRTE6E7L2 and TA-CIN for asc-us.
Treatment: pNGVL4aCRTE6E7L2 · TA-CIN — Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: HPV16 positive
Disease stage
Excluded: Stage CIN2+
Demographics
Prior therapy
Cannot have received: HPV vaccine
Prior vaccination with any HPV antigen (prophylactic or therapeutic)
Cannot have received: LEEP or cervical conization procedure
Patients who have had a prior LEEP or cervical conization procedure
Lab requirements
Blood counts
White blood cell count > 3,000; Absolute lymphocyte number > 500; Absolute neutrophil count > 1,000; Platelets > 90,000; Hemoglobulin > 9
Kidney function
Creatinine < 2.5X the institutional limit of normal
Liver function
Total bilirubin <3 X the institutional limit of normal; AST(SGOT)/ALT(SGPT) <3 X the institutional limit of normal
Patients must have adequate organ function at the time of enrollment as defined by the following parameters: White blood cell count > 3,000; Absolute lymphocyte number > 500; Absolute neutrophil count > 1,000; Platelets > 90,000; Hemoglobulin > 9; Total bilirubin <3 X the institutional limit of normal; AST(SGOT)/ALT(SGPT) <3 X the institutional limit of normal; Creatinine < 2.5X the institutional limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UAB | The University of Alabama at Birmingham · Birmingham, Alabama
- Johns Hopkins University · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03913117 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior HPV vaccine, LEEP or cervical conization procedure disqualifies patients from enrollment.
Does this trial require HPV16?
Yes, HPV16 positive is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify